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Plantar fasciitis is the most frequent cause of chronic heel 
pain. This pathology generally presents in patients who are 
40 years of age or older, overweight, sedentary, or engage in 
intense physical activity.14,32 Because of its anatomic orien-
tation and its tensile strength, the plantar fascia functions to 
prevent foot collapse. It is a piece of thick connective tissue 
that originates at the base of the calcaneus and extends dis-
tally to the phalanges. Stretching of the plantar fascia pre-
vents the displacement of the calcaneus and the metatarsals 
and helps to maintain the medial longitudinal arch. The 
plantar fascia simulates a cable between the calcaneus and 
the metatarsophalangeal joints. The windlass mechanism 
described by Hicks13 for the action of the plantar fascia 
explains that during dorsiflexion of the toes, the length of 
the plantar fascia is effectively shortened, causing an eleva-
tion of the arch. Extension of the toes increases the arc of 
tension with the metatarsophalangeal joints, similar to an 
axis or anchor point. Shortening of the plantar fascia that 
results from dorsiflexion of the hallux is the essence of the 
reel mechanism. When a complete fasciotomy is performed, 
this mechanism is lost, decreasing the stability of the arch 
and interfering with stability during the terminal stance 
phase.4,10,13,16,20,29,33
Historically, the development of plantar fasciitis was 
attributed to biomechanical defects, such as hyperprona-
tion, contributing to excessive mobility of the foot, which in 
turn increases the stress applied to musculofascial structures 
and soft tissues via an elongation of the plantar fascia.3,5,6,18 
Other studies have demonstrated that one of the principal 
causes of plantar fasciitis is mechanical overload.11,13,14,16,25
A great variety of therapies have been reported for the 
treatment of this pathology: intralesional application of ste-
roids, platelet-rich plasma, intralesional botulinum toxin A 
(BTX-A), extracorporeal shock waves, and all of these treat-
ments in combination with stretching exercises of the gastroc-
nemius, soleus muscles, or the plantar fascia.8,12,24,26,28,30,31,34
BTX-A has been employed for the treatment of musculo-
skeletal pathology, and it has recently been used for the 
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Abstract
Background: The objective of this study was to compare intramuscularly applied botulinum toxin A (BTX-A) in the 
gastroc-soleus complex with intralesional steroids for the treatment of plantar fasciitis.
Methods: The patients were randomly divided into 2 groups according to the treatment received. The patients were 
evaluated over 6 months. The evaluation scores included the Visual Analog Scale (VAS), Maryland Foot and Ankle, Foot and 
Ankle Disability Index (FADI), and American Orthopaedic Foot and Ankle Society (AOFAS) score. Moreover, patients were 
instructed to perform plantar fascia stretching exercises over the course of the study. The final number of patients was 36, 
of whom 19 received BTX-A (10 men and 9 women) and 17 (6 men and 11 women) received steroids.
Results: When compared to patients who received steroids, the patients who received BTX-A exhibited more rapid and 
sustained improvement over the duration of the study.
Conclusion: A combination of BTX-A and plantar fascia stretching exercises yielded better results for the treatment of 
plantar fasciitis than intralesional steroids.
Level of Evidence: Level I, therapeutic studies. 
Keywords: botulinum toxin A, intralesional steroids, plantar fasciitis, stretching exercise, randomized, double-blind 
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treatment of plantar fasciitis via intralesional application. The 
mechanism of action of this toxin involves blocking the 
release of acetylcholine at the neuromuscular junctions, but 
not the storage or flow of Ca++, resulting in muscular paraly-
sis. Moreover, this treatment causes proteolysis of the SNARE 
proteins, which are involved in the release of various neu-
rotransmitters, including acetylcholine. Due to these auto-
nomic and noncholinergic effects, introducing a toxin into 
noncholinergic nerve terminals permits its use for the treat-
ment of both hypersecretory states and painful pathologies.30
Another very common form of treatment for plantar fas-
ciitis is the application of intralesional steroids. However, 
there are reports of complications associated with these 
medications. One of the principal complications is the rup-
ture of the plantar fascia, which occurs in 2.4% to 5.7% of 
patients. Despite relief of the pain resulting from the rup-
ture, it has been associated with instability of the lateral col-
umn and calcaneocuboid joint pain.1,15
The purpose of this study was to compare the use of intra-
muscularly applied BTX-A in the gastroc-soleus muscle 
complex and the intralesional application of steroids. Both of 
these methods were combined with education regarding the 
disorder and a plantar fascia stretching program.
Methods
This study was a prospective, experimental, randomized, 
double-blinded, and controlled clinical trial. The patients 
who came to our clinic were recruited for the study and 
signed informed consent forms, which were previously 
approved by the ethics committee of the medical research 
department at our hospital.
The inclusion criteria were the following: skeletally 
mature, with heel pain at the insertion of the plantar fascia or 
in the anteromedial tuberosity of the calcaneus; failure of 
conservative treatment for 3 months, which consisted of 
pads in ordinary shoe and NSAID; and no previous injec-
tions. We excluded patients with associated pathologies, 
such as knee or ankle dysfunction, osteoarthritis, rheumatoid 
arthritis, ankylosing spondylitis, Reiter’s syndrome, neuro-
logical abnormalities, mental retardation or psychiatric 
abnormalities, cutaneous infection, or a history of infection 
in the previous 3 months, at the application site. We also 
excluded patients with adverse reactions to the applied com-
ponents, those who voluntarily asked to leave the study, and 
those who did not complete the follow-up appointments.
The patients were divided into 2 groups: group A, who 
received BTX-A, and group B, who received injections 
with steroids (dexamethasone isonicotinate). Stretching 
exercises for the plantar fascia were demonstrated to both 
groups7 and consisted of the patient crossing the affected 
leg over the contralateral leg, then the patient pulled the toes 
back toward the shin until a stretch was felt in the arch or in 
the plantar fascia; moreover, patients received information 
regarding their disorder. The patients were randomly 
assigned into either group using the Alea-T-7/33 program. 
All of the patients attended the 6 visits. During the initial 
evaluation, we completed a physical examination, the 
informed consent forms were signed, and initial clinical 
scale measurements were made using the Visual Analog 
Scale (VAS), the Maryland Foot and Ankle scale, the 
American Orthopaedic Foot and Ankle Society (AOFAS), 
and the Foot and Ankle Disability Index (FADI). The 
assigned medication was also applied at the initial evalua-
tion. The patients were evaluated 15 days following the 
application of the medication and at 1, 2, 4, and 6 months. 
The clinical measures were assessed at all visits. The mea-
surements were made by a blinded investigator who was 
unaware of the patient group assignments.
A total of 40 patients were enrolled in this study. Of these, 
4 were eliminated due to loss to follow-up (1 in the toxin 
group and 3 in the steroid group). The final number of 
patients was 36, of whom 19 received BTX-A (10 men and 
9 women) and 17 (6 men and 11 women) received steroids. 
The mean age of those who were administered the toxin was 
41.6 years (29-53 years), and the mean age of the steroid 
group was 44.5 years (32-54 years). With the numbers avail-
able, no significant difference could be detected between the 
2 groups with respect to age. The 4 patients who were lost 
did not come back for follow-up after treatment.
Scales Used for Evaluation
We decided to use several scales to evaluate foot and ankle 
pathology to obtain improved information and to perform a 
detailed analysis of the evolution of the patients who 
received either treatment. The VAS evaluated pain on a 
numerical scale from 0 to 10, where 0 signified no pain and 
10 signified the worst pain experienced by the patient. This 
scale was complemented by a color scale, on which green 
signified no pain and bright red signified the most intense 
pain that the patient had experienced. We also used the 
Maryland Foot Score,22 which was divided into several sec-
tions that evaluated pain (a score of 45 signified no pain, 
and 0 indicated an incapacity to work). Among the sections 
of this scale were function, which was divided into two 
additional sections (motion and functional activities), and a 
section that evaluated the shape of the foot. The best score 
possible was 100, indicating no problem with the foot, and 
the lowest score was 0. The AOFAS included a scale for the 
hindfoot, which evaluated the broad categories of foot pain, 
function, and alignment. Similar to the other scales, the 
highest score for the AOFAS was 100.17 We decided to 
include the FADI score because plantar fasciitis presents in 
patients who actively participate in sports, and this pathol-
ogy can cause them to become disabled. The FADI scale 
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evaluated several metrics, including activities such as 
standing up, walking on flat or irregular surfaces, walking 
on inclined planes, and the amount of time one could walk 
without difficulty. Moreover, this scale included a module 
for sports activities and foot and ankle pain. The highest 
score possible was 136 points.21
Application of Botulinum Toxin A
The patients were placed in the prone position with the feet 
raised off the examination table, relaxing the calf muscula-
ture. The sites of application were 2 points (medial and 
lateral) at the site of greatest thickness of each calf muscle, 
perpendicular to the muscular mass of each calf. One hun-
dred units of toxin were applied to each muscle belly, and 
1 application of 50 U was administered to the soleus, for a 
total of 250 U; all applications were guided by anatomical 
landmarks (postero-medial into the calf). Following the 
treatment, dorsiflexion and plantarflexion of the affected 
foot were performed. The stretching exercises were initi-
ated up to 7 days following the application of the toxin, 
permitting the patient to perform activities of daily living 
with ease. The patients were not immobilized.
Application of Steroids
The patients in group B received the medication via injec-
tion into the medial plantar surface of the foot, placing the 
needle just superior to the plantar fascia. A combination of 
2% lidocaine (2 mL) and 8 mg of dexamethasone (2 mL) 
was used. Similar to the other group, plantar fascia stretch-
ing exercises were initiated at 7 days following the injec-
tion, permitting easy performance of normal activities of 
daily living. The patients were not immobilized.
Data Analyses
For parametric distributions, we used the Student’s t test; 
for nonparametric distributions, the Wilcoxon rank test was 
used. We used analysis of variance (ANOVA) tests to ana-
lyze intergroup variability and considered P ≤ .05 to be 
statistically significant. Electronic data processing and 
descriptive and inferential statistics were performed using 
the STATA-IC-10-2008 program.
Results
No significant differences were identified in the initial 
evaluation between the 2 groups with respect to the results 
obtained for pain using the VAS (7.1 ± 1.75 toxin group vs 
7.7 ± 1.32 steroid group). At the second patient visit, we 
observed a decrease in pain perception in both groups, but 
there was no difference between the VAS scores (3.0 ± 1.56 
for the toxin group vs 4.0 ± 1.37 for the steroid group). 
Beginning with the third visit, the group receiving 
BTX-A exhibited a significant improvement compared to 
the steroid group; we found that the toxin group scored 1.9 
± 1.51 points on the VAS, whereas the steroid group scored 3.4 
± 1.24 points. At visits 4 and 5, the patients receiving BTX-A 
scored 1.6 ± 2.07 and 1.5 ± 2.17 points, respectively, whereas 
for the same visits, the steroid group scored 3.6 ± 1.94 and 3.7 
± 1.96, respectively. At the end of the study, the patients 
receiving BTX-A averaged 1.1 ± 1.5 points, whereas for the 
steroid group, the final average was 3.8 ± 1.15 points 
(Table 1). For group A (BTX-A), the Wilcoxon rank tests 
indicated statistically significant differences in pain scores 
at visit 1 compared to visits 2, 3, 4, 5, and 6. The scores for 
visit 2 differed significantly from those for visits 1, 3, 4, 5, 
and 6. The scores for visit 3 differed significantly from 
those for visits 1, 2, and 6. The scores for visit 4 differed 
statistically from those for visits 1, 2, and 6. For group B 
(steroids), the scores for visit 1 differed from those for vis-
its 2, 3, 4, 5, and 6. The scores for visit 2 differed from 
those for visits 1 and 3 (Table 1).
At the initial evaluation, no differences were observed in 
the mean Maryland Foot and Ankle score between the 
patient groups; however, following the second visit and 
until the final evaluation, the BTX-A group exhibited sig-
nificantly better results than those of the steroid group 
(Table 2). Using the ANOVA analyses, we observed that 
group A (BTX-A) exhibited statistically significant differ-
ences in the scores for visit 1 compared to visits 2, 3, 4, 5, 
and 6. The scores for visit 2 were significantly different 
from those for visits 1, 3, 4, 5, and 6. For group B (steroids), 
the scores for visit 1 were different from those for visits 2, 
3, 4, 5, and 6. The scores for visit 2 were different from 
those for visits 1 and 3 (Table 2).
At the beginning of the study, the two groups did not 
exhibit differences between their AOFAS scores (46.0 ± 
14.83 for the toxin group vs 46.8 ± 11.23 for the steroid 
group); however, at the second visit, a significant improve-
ment was observed in the toxin group (85.2 ± 10.66 points) 
versus the steroid group (72.8 ± 8.01). Moreover, in the fol-
lowing visits, significant differences were observed in favor 
of the toxin group (Table 3). For group A, ANOVA tests 
indicated statistically significant differences in the scores 
for visit 1 compared to visits 2, 3, 4, 5, and 6. The scores for 
visit 2 were significantly different from those for visits 1, 3, 
4, 5, and 6. The scores for visit 3 were different from those 
for visits 1, 2, 4, 5, and 6. The scores for visit 4, 5, and 6 
were significantly different from those for visits 1, 2, and 3. 
For group B, the scores for visit 1 were different from those 
for visits 2, 3, 4, 5, and 6. The scores for visit 2 were differ-
ent from those for visits 1 and 3 (Tables 1 and 2).
The initial FADI scores were similar for the 2 groups 
(75.4 ± 6.92 points for the toxin group and 77.0 ± 3.21 
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points for the steroid group). We observed a significant 
improvement in the FADI scores beginning with the second 
visit, and this improvement was maintained through the end 
of the study, clearly indicating a significant improvement 
for the group treated with BTX-A (Table 4). For group A, 
the ANOVA test indicated statistically significant differ-
ences between the scores for visit 1 compared to those for 
visits 2, 3, 4, 5, and 6. The scores for visit 2 differed signifi-
cantly from those for visits 1, 3, 4, 5, and 6. The scores for 
visit 3 differed significantly from those for visits 1, 2, and 5. 
The scores for visit 4 differed significantly from those for 
visits 1 and 2. The scores for visit 5 differed significantly 
from those for visits 1, 2, and 3. The scores for visit 6 dif-
fered significantly from those for visits 1, 2, and 3. For 
group B, the scores for visit 1 differed from those for visits 
2, 3, 4, 5, and 6. The scores for visit 2 differed from those 
for visits 1 and 3 (Tables 1 and 2).
We did not have any adverse reaction with the treatments.
Discussion
Babcock et al2 performed a double-blinded, randomized, 
placebo-controlled study with 27 patients with plantar fas-
ciitis. The authors administered 70 U of BTX-A into 2 sites 
per foot (medially on the heel near the calcaneal tuberosity 
and in the plantar arch of the foot, 1 inch anterior and 
medial). The control group received saline solution. This 
study evaluated VAS scores, Maryland Foot scores, and 
pressure algometry measurements; these metrics were 
evaluated following the injection and at 3 and 8 weeks. The 
authors observed significant changes in all of these metrics 
in the group treated with BTX-A. In our study, we observed 
that VAS scores were improved in both groups of patients; 
however, this difference was statistically significant only 
Table 1. Comparison Between Groups Evaluating Visual Analogue Scale (VAS), With P ≤ .05
Group A Group B  
 Value SD Value SD P  
Initial 7.1 ±1.75 7.7 ±1.32 ns  
Visit 2 3.0 ±1.56 4.0 ±1.37 .02  
Visit 3 1.9 ±1.51 3.4 ±1.24 .0004  
Visit 4 1.6 ±2.07 3.6 ±1.94 .0009  
Visit 5 1.5 ±2.17 3.7 ±1.96 .0005  
Final 1.1 ±1.50 3.8 ±1.15 .0005  
 
Wilcoxon Rank Test (VAS)
 
 
    FADI
  
 
 AOFAS
Visit Group A Group B Group A Group B Group A Group B
1 vs 2 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001
1 vs 3 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001
1 vs 4 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001
1 vs 5 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001
1 vs 6 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001 P ≤ .0001
2 vs 3 P ≤ .0001 P = .025 P ≤ .0001 P = .005 P = .002 P = .017
2 vs 4 P ≤ .0001 ns P ≤ .0001 P = .49 P = .001 ns
2 vs 5 P = .001 ns P ≤ .0001 ns P ≤ .0001 ns
2 vs 6 P = .001 ns P ≤ .0001 ns P ≤ .0001 ns
3 vs 4 ns ns P = .056 ns P = .039 ns
3 vs 5 ns ns P = .032 ns P = .20 ns
3 vs 6 P = .004 ns ns ns P = .003 ns
4 vs 5 ns ns ns ns ns ns
4 vs 6 P = .033 ns ns ns ns ns
5 vs 6 ns ns ns ns ns ns
FADI = Foot and Ankle Disability Index; AOFAS = American Orthopaedic Foot and Ankle Society.
ANOVA
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Table 2. Comparison Between Groups With Maryland Foot 
Ankle Score, With P ≤ .05
Group A Group B  
 Value SD Value SD P
Initial 62.1 ±9.84 60.0 ±11.87 ns
Visit 2 87.8 ±11.18 76.3 ±15.41 .002
Visit 3 92.8 ±8.40 84.6 ±15.05 .02
Visit 4 94.3 ±10.58 83.5 ±16.05 .004
Visit 5 94.3 ±10.62 79.2 ±17.15 .0002
Final 94.4 ±10.64 79.2 ±14.96 .0001
 Maryland Foot Score  
Visit Group A Group B  
1 vs 2 P ≤ .0001 P ≤ .0001  
1 vs 3 P ≤ .0001 P ≤ .0001  
1 vs 4 P ≤ .0001 P ≤ .0001  
1 vs 5 P ≤ .0001 P ≤ .0001  
1 vs 6 P ≤ .0001 P ≤ .0001  
2 vs 3 P = .002 P = .030  
2 vs 4 P = .004 ns  
2 vs 5 P = .004 ns  
2 vs 6 P = .003 ns  
3 vs 4 ns ns  
3 vs 5 ns P = .042  
3 vs 6 ns P = .35  
4 vs 5 ns ns  
4 vs 6 ns ns  
5 vs 6 ns ns  
Table 3. Comparison Between Groups With American 
Orthopaedic Foot and Ankle Society (AOFAS) Score, With  
P ≤ .05
Group A Group B  
 Value SD Value SD P
Initial 46.0 ±14.83 46.8 ±11.2 ns
Visit 2 85.2 ±10.66 72.8 ±8.01 .00006
Visit 3 89.4 ±9.92 77.1 ±9.85 .00008
Visit 4 92.3 ±11.03 76.8 ±13.73 .00006
Visit 5 92.8 ±10.52 74.4 ±13.34 .000006
Final 93.2 ±9.31 74.8 ±10.29 .00000006
for patients treated with BTX-A. In the visit-by-visit analy-
sis, we observed a rapid and sustained improvement in the 
patients treated with BTX-A compared to the steroid group.
In a randomized study, DiGiovanni et al8 evaluated 
82 patients using 1 of 2 types of stretching programs: 
one group performed a plantar fascia stretching program, 
and the other group performed an Achilles tendon stretch-
ing program. The different programs were evaluated using 
the Foot Function Index. All exhibited improvement with 
the exercises, but based on evaluation with the pain sub-
scale, the patients performing the plantar fascia stretching 
program improved on item 1 (the highest degree of pain 
felt) and item 2 (the first steps in the morning). The princi-
pal goal of the plantar fascia stretching program is to recre-
ate the windlass (reel) mechanism and to limit the repetitive 
microtrauma and chronic inflammation that occurs prior to 
the first steps in the morning or following prolonged peri-
ods of inactivity.
Placzek et al24 examined 9 patients diagnosed with 
chronic plantar fasciitis for a mean duration of 14 months. 
The patients were treated with 200 U of BTX-A; at the 
evaluation conducted 6 months following the procedure, 
all patients exhibited a 50% reduction in pain when sup-
porting their body weight. This effect was maintained over 
the 14 weeks of treatment. One study reported that changes 
occur in the elasticity of the plantar fascia during plantar 
fasciitis, decreasing the mobility of the foot, reducing con-
tracture, and resulting in the development of heel pain.27 
Our study focused on recovering the windlass mechanism, 
as described by Hicks et al,13 by relaxing the musculature 
of the gastroc-soleus complex via intramuscular applica-
tion of BTX-A. We observed greater and more sustained 
improvement in patients who received BTX-A; the patients 
also reported significant improvement in their symptom-
atology and in their activities of daily living. The same 
results were obtained with respect to the scales used to 
measure pain and functionality (ie, AOFAS, FADI, and 
Maryland Foot and Ankle scores). Both groups exhibited 
improvement at the second visit; however, this improve-
ment was greater and more sustained in the group receiving 
BTX-A.
In one study, it was reported that exercises stretching the 
plantar fascia result in a limited short-term benefit; how-
ever, it was also noted that this effect might have reflected a 
significant longer term improvement. Moreover, with 
respect to the use of BTX-A, this study reports both 
Table 4. Comparison Between Groups With Foot and Ankle 
Disability Index (FADI) Score, With P ≤ .05
Group A Group B  
 Value SD Value SD P
Initial 75.4 ±6.92 77.0 ±3.20 ns
Visit 2 90.6 ±7.34 82.4 ±5.51 .00007
Visit 3 94.0 ±7.30 85.5 ±5.22 .00007
Visit 4 94.9 ±7.52 84.7 ±6.53 .00003
Visit 5 95.2 ±7.64 82.8 ±6.67 .000004
Final 95.0 ±7.27 83.0 ±6.41 .000004
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short-term and long-term improvement. The use of steroids, 
however, appears to generally result in short-term patient 
improvement, along with the described complications.31 
Investigators have also reported that rigidity in the gastroc-
soleus complex decreases the dorsiflexion movement of the 
foot, predisposing the individual to the development of 
chronic foot problems. Contracture of the gastrocnemius-
soleus muscular complex, defined as a limitation in dorsi-
flexion of less than or equal to 10 degrees, is present in as 
many as 88% of patients.9
An increase in hamstring muscle tension can increase 
the chance of developing plantar fasciitis by up to 8.7-
fold; moreover, a body mass index (BMI) greater than 
35 increases the risk of plantar fasciitis by 2.4.19 It has been 
reported that there is an association between plantar fasciitis 
and gastrocnemius contracture, which presents as limited 
dorsiflexion in the majority of patients.23 We did not evaluate 
BMI in our study; however, it is a factor that needs to be 
z: considered when evaluating patients with this type of 
pathology.
In conclusion, we found that a combination of BTX-A 
applications into the gastroc-soleus complex and plantar 
fascia stretching exercises yielded better results for the 
treatment of plantar fasciitis than intralesional steroids. It is 
important to note that patients must perform plantar fascia 
stretching exercises to obtain a rapid and sustained improve-
ment of plantar fasciitis.
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